Psoriasis is a papulosquamous chronic skin disease that requires life-long management. Ixekizumab (IXE) is a high-affinity selective monoclonal antibody against interleukin (IL)-17A which is registered treating moderate-to-severe plaque psoriasis. The purpose of this thesis work is to assess the outcomes of patients who interrupted the treatment and were subsequently retreated with IXE, as well as to investigate if after the temporary suspension the patients will ever be able to reach again their best clinical score obtained before. Information was collected from patients available in the Department of Dermatology, in the University of Debrecen. The investigation was authorized by the Local Ethics Committee (H.0046-2019). The patients started the normal regimen of IXE, after induction, receiving 80 mg every 4 weeks until the treatment was stopped. After that, further financial support was requested from responsible bureaus for the treatment continuation. Waiting upon approval patients were suspended an average of 94 days until re-start was realized. After an average of 24 weeks of the re-start of the treatment, 75% of the patients reached symptom-free state, and the rest improved an average of 85% compared to their clinical status at the beginning of re-start. IXE demonstrated to be highly effective in the clearance of psoriatic skin even after the treatment was interrupted taking a relatively short time to regain efficacy and with no encountered clinically significant side effects.